Cantor Fitzgerald Assigns a Buy Rating on Theravance Biopharma (TBPH)

Cantor Fitzgerald analyst Louise Chen assigned a Buy rating to Theravance Biopharma (TBPH) on April 7 and set a price target of $55. The company’s shares opened today at $23.80.

Chen commented:

“. We believe it is a good time to take another look at TBPH given its inexpensive valuation, and ahead of important catalysts this year. We also note that TBPH’s cash and equivalents totaled $517.1MM as of 12/31/18. It appears well-positioned to receive over $1B in milestones and payments, but its market cap is only ~$1.3B. Therefore, we think the peak sales potential of TBPH’s organ-selective Trelegy, are all underappreciated. Our positive investment thesis supports our OW rating and 12-month PT of $55.”

According to TipRanks.com, Chen is a 5-star analyst with an average return of 12.6% and a 47.1% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amneal Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Theravance Biopharma with a $47.50 average price target.

See today’s analyst top recommended stocks >>

Based on Theravance Biopharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $50.19 million. In comparison, last year the company had a GAAP net loss of $65.09 million.

Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of small molecule medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin.